BICYCLE THERAPEUTICS PLC
BCYCDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
BT8009
Urinary Bladder Neoplasm
Gemcitabine + cisplatin Or carboplatin
Metastatic Urothelial Cancer
BT7480
Advanced Solid Tumor
Zelenectide pevedotin (BT8009)
Non-Small Cell Lung Cancer
BT1718
Advanced Solid Tumours
nuzefatide pevedotin (BT5528)
Pancreatic Ductal Adenocarcinoma (PDAC)
BT5528
Advanced Solid Tumor Historically Known for High EphA2 Expression
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BT8009 | Phase 3 | Urinary Bladder Neoplasm | - | - |
Gemcitabine + cisplatin Or carboplatin | Phase 3 | Metastatic Urothelial Cancer | - | - |
BT7480 | Phase 2 | Advanced Solid Tumor | - | - |
Zelenectide pevedotin (BT8009) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BT1718 | Phase 2 | Advanced Solid Tumours | - | - |
nuzefatide pevedotin (BT5528) | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
BT5528 | Phase 2 | Advanced Solid Tumor Historically Known for High EphA2 Expression | - | - |
Frequently asked questions
What is in BICYCLE THERAPEUTICS PLC's drug pipeline?→
CatalystAlert tracks 7 drug candidates in BICYCLE THERAPEUTICS PLC's (BCYC) pipeline across Phase 3, Phase 2. Its lead program is BT8009 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BICYCLE THERAPEUTICS PLC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BICYCLE THERAPEUTICS PLC (BCYC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BCYC biotech catalysts?→
Add BCYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BICYCLE THERAPEUTICS PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.